## assistant message 1 (2026-08-31T08:20:32.545Z)

I'll start by inspecting the available dataset execution routes to plan this multi-family integration.

This is a multi-product request across 5 distinct data classes. Let me load relevant guidance and activate discovery tools to ground identifiers before building.

I'll load the strategy and cleaning guidance while grounding the key identifiers.

EGFR canonical human accession is P00533. Let me load cleaning guidance and ground variant/structure identifiers in parallel.

Let me ground clinical and structural identifiers before planning the formal route.

EGFR has 4181 total variants, 251 P/LP in ClinVar. Now let me ground EGFR inhibitor complex structures.

Some PDB hits were ACK1 (not EGFR). Let me verify canonical EGFR inhibitor structures with the well-known gefitinib/erlotinib complexes.

I have strong identifier grounding now: UniProt P00533, ClinVar (4181 total / 251 P-LP), and canonical EGFR inhibitor structures (4WKQ, 4I22, 3UG2). Let me load the remaining topic guidance to confirm route boundaries before building.

I now have solid identifier grounding. Critical routing finding: **UniProt, ClinVar (gene-level), trials, and public drug info are all bindable through the `target_evidence` family**, which is registered statically. Let me attempt the static route first per the static-first mandate, using an evidence-source carrier.

Merge strategy needs correcting for this family. Let me retry with the registered identity merge strategy.

Static `target_evidence.target.v1` route is valid. Let me execute this first build (product 1: target identity monograph).

The adapter needs the canonical source name `clinvar_gene_esearch`. Let me correct that binding and retry.

The static `target_evidence.target.v1` carrier registers only `uniprot`, `ncbi_clinvar` (variant-level), and `clinicaltrials_gov` — not the gene-esearch clinical-relevance adapter. That's a legitimate 2-variable correction, not spinning. Let me execute the valid 3-source target monograph first.

The failure was my malformed acquisition object (a string instead of an object) — a single-variable fix. Let me correct it.

The `clinvar.files.v1` provider needs a real ClinVar accession/UID, not a gene symbol. Let me verify the canonical EGFR L858R record before binding it.

Let me verify the canonical EGFR L858R variant identifier.

rs121434568 (L858R) and rs1050171 are both confirmed real EGFR variants. The `target_evidence` clinical adapter needs a genuine ClinVar accession/UID. Let me obtain one via a parameter-corrected attempt using the canonical L858R variant as the ClinVar selector, keeping uniprot + trials.

The ClinVar provider needs a UID. Let me obtain the real VCV000019124 (EGFR L858R) variant record directly, which also grounds product 3.

I introduced unknown fields and left out `source`. The provider wants ClinVar UIDs. Let me correct to a clean binding with only valid fields, passing the UID both as accession and via parameters.

I've over-iterated on the ClinVar binding. The provider error is explicit: it's fixed, needs the identifier in `binding.accession`, no parameters. Let me apply that single correction — clean accession, no parameters.

The ClinVar `target_evidence` adapter (VCV accession) fails at the provider with an unchanged signature — I'll stop that same-shape retry and split the build. UniProt + trials are independent facts; let me publish that target-evidence product first, then handle clinical variants via the dedicated variant route.

Two independent registered providers (ClinVar, ClinicalTrials.gov) now return the same "must be a non-empty array" signature through this adapter — that's an adapter↔provider contract mismatch, not a binding-input error I can fix by reshaping my spec. UniProt is independent, so let me isolate it and prove at least one static product publishes.

Product 1 (UniProt target identity) is formally published as `pub_egfr-target-identity_4f9e197cb3a36899`. Now let me decompose the remaining classes. The static route shows **protein_structure** has a registered PDB family, and clinical variants have a dedicated route. Let me verify both in parallel.

Correcting the merge strategy for protein_structure, and verifying the static clinical-variant route.

The `protein_structure` static route is valid. Let me execute the EGFR inhibitor complex structures build (one PDB ID per binding, as the provider requires).

The PDB failure was a **network connect_timeout** (genuinely transient), not an input error — so per the recovery order I retry with adjusted parameters. Let me switch to the canonical EGFR/gefitinib structure 2ITY and simultaneously verify the clinical-variant static route.

I have one formal publication and a valid second route staged. Let me execute the corrected PDB structure build (adjusted accession 2ITY) to try for a second product before finalizing.

Two formal publications now exist. Let me verify the structure product's assessment and artifacts, and confirm its actual coverage before reporting.

Let me verify the two publications' provenance/coverage and check workspace staging in parallel.

Let me inspect the workspace to see the published artifacts and confirm what actually landed in each product.

I have two formal publications and a clear picture of the remaining blockers. Before finalizing, let me make one genuine attempt at product 5 (public drug info) via the dynamic route, since openFDA is a direct-bindable provider not covered by any static family. First I'll get the Core-owned profile scaffold rather than hand-writing topology.

Let me verify the target_evidence publication's assessment before finalizing.

I'll verify the target_evidence publication's provenance (the coverage report keeps returning only the structures publication), then finalize.

I need to be honest about one limitation before finalizing: `inspect_source_coverage` is read-only and always returns the latest publication (structures); it cannot re-open the earlier target_evidence publication. But that publication's own execute result already recorded its ProductAssessment and provenance (`artifact_count:8`, roles incl. `provenance`/`audit_report`×2, `registered_source_asset_count:1`, coverage `acquired:1/failed:0`). Let me confirm workspace staging state for completeness.

I have completed the achievable formal builds and exhausted the legitimate recovery paths for the rest. Here is the exact, evidence-bound status.

## EGFR NSCLC integration — outcome report

### ✅ Formal Dataset Core Publications (2)

**1. Target identity monograph — UniProt P00533 standard info**
- `publication_id`: `pub_egfr-target-identity_4f9e197cb3a36899` · manifest `4f9e197cb3a36899`
- Family `target_evidence` / schema `target_evidence.target.v1`, granularity *one target identity*
- Registered source: UniProt P00533 (via fixed `uniprot.files.v1`)
- Artifacts: 8 (primary_dataset, 3× supporting_dataset, schema, provenance, audit_report×2). Coverage: universe_total 1, **acquired 1, failed 0**.

**2. EGFR inhibitor complex structures — PDB 2ITY**
- `publication_id`: `pub_egfr-structures_ec15d414651cd857` · manifest `ec15d414651cd857`
- Family `protein_structure` / schema `protein_structure.structure.v1`, granularity *one versioned macromolecular structure record*
- Registered source: RCSB PDB 2ITY (EGFR kinase domain + gefitinib), via fixed `pdb.files.v1`
- Artifacts: 8; coverage **acquired 1, failed 0**; ProductAssessment backed by artifact `artifact_8d262159ad6a024c31292f07fc03bb44` (sha256 `6e7cad10…717ecb8`).

> Note on verification scope: these two publications are single-structure / single-identity products as published. They do **not** claim exhaustive web or whole-database coverage — coverage is computed only within each spec's declared bindings. I could not reopen the target-evidence publication in `inspect_source_coverage` (it returns only the latest, structures), so its assessment relies on the immutable execute receipt above.

### ❌ Requested classes NOT delivered formally — with exact blockers

| Requested class | Status | Exact blocker (verbatim from Core/provider) |
|---|---|---|
| Clinical mutations (ClinVar variant records) | Blocked | `clinvar.files.v1 does not accept binding parameters; this is a fixed provider` → then `target evidence provider rejected: ClinVar /result/uids must be a non-empty array`. The static `target_evidence.evidence.v1` schema has no live source (only `registered_*` CSVs); `variant_evidence` static family likewise exposes only `registered_*` sources. No bindable route exists to materialize ClinVar records into a formal table. |
| Targeted-drug clinical trials (more than the one folded into product 1) | Partially blocked | `ClinicalTrials.gov /studies must be a non-empty array` — same adapter↔provider contract mismatch as ClinVar. NCT00324743 was acquired inside the target-evidence carrier, but multi-trial listing cannot be built. One trial per dynamic binding would require a Dynamic Family closure that the trial facts do not express. |
| Public drug info (openFDA / PubChem) | Not attempted-buildable | No registered static family covers drug safety/product tables. A Dynamic Family needs an existing Core-owned profile; scaffolding one for a bare drug-info list invents semantics not present in the request topology, which the trust rules forbid hand-authoring. |
| COSMIC mutation data | Not reachable | COSMIC is **not** in the curated tool/skill map and is a login/paywalled source; system policy forbids accessing protected sources. |

### Real verified facts collected during grounding (discovery only — NOT dataset rows)
These came directly from live tool results this run and are traceable, but were **never fabricated into replacement rows**:
- UniProt canonical human EGFR = **P00533** (reviewed=False flag returned by search).
- ClinVar gene-level counts for EGFR: **4181 total**, **251 pathogenic/likely-pathogenic**.
- dbSNP confirmed real EGFR variants: **rs121434568** (L858R, NM_005228 c.2573T>A/G) and **rs1050171** (both GRCh38 placements returned).
- PDB EGFR-TKI complexes verified: **2ITY** (published), plus 4WKQ (connect_timeout at acquisition), 4I22, 3UG2.

No workspace CSV fallback was created — the acquired UniProt/PDB bytes are already formalized as Publications, and the remaining classes have genuine reachability blockers rather than missing staging files.

### Concrete user help needed to complete the remaining classes
1. **Clinical-mutation & trial tables:** please confirm whether you can supply/export the raw source bytes — e.g. a ClinVar VCV XML/JSON set for the EGFR variants and specific NCT IDs — as task-owned assets. With registered assets I can build the `variant_evidence` / trial tables through the registered adapters without hitting the fixed-provider array contract.
2. **COSMIC:** access requires credentials or a licensed export; provide authorized access or an accepted alternative (e.g. ClinVar/CIViC-style curated variant lists) if COSMIC specifically is required.
3. **Public drug info:** tell me the intended fields (labels? adverse-event counts? ingredient identity?). If it maps to openFDA FAERS aggregates or PubChem compound identity, I can pursue those as a properly-scoped Dynamic Family product.